Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Lucas Moreno

Showing results (111-120 of 122) with videos related to

Pageof 13
Sort By:
Clinical & Translational Oncology : Official Publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico|April 10, 2024
ECLIM-SEHOP: how to develop a platform to conduct academic trials for childhood cancerAntonio Juan-Ribelles, Francisco Bautista, Adela Cañete, et al.
European Journal of Cancer (Oxford, England : 1990)|October 31, 2020
Impact of COVID-19 in paediatric early-phase cancer clinical trials in Europe: A report from the Innovative Therapies for Children with Cancer (ITCC) consortiumAlba Rubio-San-Simón, Nicolas André, Maria Giuseppina Cefalo, et al.
European Journal of Cancer (Oxford, England : 1990)|September 24, 2019
A tailored molecular profiling programme for children with cancer to identify clinically actionable genetic alterationsSally L George, Elisa Izquierdo, James Campbell, et al.
European Journal of Cancer (Oxford, England : 1990)|November 15, 2025
Paediatric Strategy Forum for medicinal product development of agents targeting GD2 ganglioside in children and adolescents with cancerSteven G DuBois, Lucas Moreno, Rochelle Bagatell, et al.
Journal of the National Cancer Institute|August 25, 2025
International neuroblastoma risk group consortium: a model of a networking for rare cancersSusan L Cohn, Wendy B London, Gudrun Schleiermacher, et al.
European Journal of Cancer (Oxford, England : 1990)|August 1, 2025
Prognostic factors of early mortality in children and adolescents with relapsed/refractory solid tumors participating in dose-finding trials in the targeted and immune therapies era: An ITCC studyFernando Carceller, Francisco Bautista, Harm Van Tinteren, et al.
European Journal of Cancer (Oxford, England : 1990)|July 13, 2020
Accelerating drug development for neuroblastoma: Summary of the Second Neuroblastoma Drug Development Strategy forum from Innovative Therapies for Children with Cancer and International Society of Paediatric Oncology Europe NeuroblastomaLucas Moreno, Giuseppe Barone, Steven G DuBois, et al.
Pediatric Blood & Cancer|June 2, 2024
Cancer is not a risk factor for severe COVID-19 in children, except in patients with recent allogeneic hematopoietic stem cell transplantation or comorbiditiesPablo Velasco Puyó, Alfredo Tagarro, Susana Garcia-Obregon, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|December 12, 2025
Dinutuximab Beta Added to Temozolomide-Based Chemotherapy for Children With Relapsed and Refractory Neuroblastoma: Results of the ITCC-SIOPEN BEACON Immuno Phase II TrialJuliet C Gray, Rebekah Weston, Cormac Owens, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|January 8, 2024
Bevacizumab, Irinotecan, or Topotecan Added to Temozolomide for Children With Relapsed and Refractory Neuroblastoma: Results of the ITCC-SIOPEN BEACON-Neuroblastoma TrialLucas Moreno, Rebekah Weston, Cormac Owens, et al.
Pageof 13

Showing results (111-120 of 122) with videos related to

Sort By:
Pageof 13
Clinical & Translational Oncology : Official Publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico|April 10, 2024
ECLIM-SEHOP: how to develop a platform to conduct academic trials for childhood cancerAntonio Juan-Ribelles, Francisco Bautista, Adela Cañete, et al.
European Journal of Cancer (Oxford, England : 1990)|October 31, 2020
Impact of COVID-19 in paediatric early-phase cancer clinical trials in Europe: A report from the Innovative Therapies for Children with Cancer (ITCC) consortiumAlba Rubio-San-Simón, Nicolas André, Maria Giuseppina Cefalo, et al.
European Journal of Cancer (Oxford, England : 1990)|September 24, 2019
A tailored molecular profiling programme for children with cancer to identify clinically actionable genetic alterationsSally L George, Elisa Izquierdo, James Campbell, et al.
European Journal of Cancer (Oxford, England : 1990)|November 15, 2025
Paediatric Strategy Forum for medicinal product development of agents targeting GD2 ganglioside in children and adolescents with cancerSteven G DuBois, Lucas Moreno, Rochelle Bagatell, et al.
Journal of the National Cancer Institute|August 25, 2025
International neuroblastoma risk group consortium: a model of a networking for rare cancersSusan L Cohn, Wendy B London, Gudrun Schleiermacher, et al.
European Journal of Cancer (Oxford, England : 1990)|August 1, 2025
Prognostic factors of early mortality in children and adolescents with relapsed/refractory solid tumors participating in dose-finding trials in the targeted and immune therapies era: An ITCC studyFernando Carceller, Francisco Bautista, Harm Van Tinteren, et al.
European Journal of Cancer (Oxford, England : 1990)|July 13, 2020
Accelerating drug development for neuroblastoma: Summary of the Second Neuroblastoma Drug Development Strategy forum from Innovative Therapies for Children with Cancer and International Society of Paediatric Oncology Europe NeuroblastomaLucas Moreno, Giuseppe Barone, Steven G DuBois, et al.
Pediatric Blood & Cancer|June 2, 2024
Cancer is not a risk factor for severe COVID-19 in children, except in patients with recent allogeneic hematopoietic stem cell transplantation or comorbiditiesPablo Velasco Puyó, Alfredo Tagarro, Susana Garcia-Obregon, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|December 12, 2025
Dinutuximab Beta Added to Temozolomide-Based Chemotherapy for Children With Relapsed and Refractory Neuroblastoma: Results of the ITCC-SIOPEN BEACON Immuno Phase II TrialJuliet C Gray, Rebekah Weston, Cormac Owens, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|January 8, 2024
Bevacizumab, Irinotecan, or Topotecan Added to Temozolomide for Children With Relapsed and Refractory Neuroblastoma: Results of the ITCC-SIOPEN BEACON-Neuroblastoma TrialLucas Moreno, Rebekah Weston, Cormac Owens, et al.
Pageof 13